Doseology Sciences unit signs manufacturing deal

Mr. Tim Corkum reports DOSEOLOGY COMPLETES EXTENSIVE NORTH AMERICAN DILIGENCE, SECURING STRATEGIC MANUFACTURING AGREEMENT VIA U.S. SUBSIDIARY DOSEOLOGY USA INC. Doseology Sciences Inc.'s wholly owned Florida subsidiary, Doseology USA Inc., has executed a confidential manufacturing agreement with a leading North American production partner. This milestone represents a step in Doseology's operational evolution -- establishing the commercial infrastructure, manufacturing capacity and regulatory foundation required to support the company's transition from development of its oral stimulant pouches to full market readiness. "This is much more than a manufacturing agreement; it's a defining moment as it enables Doseology to move from R&D [research and development] to commercial deployment," said Tim Corkum, president and chief operating officer of Doseology. "Through Doseology USA Inc., we've secured an American partner that delivers the scale, quality and integrity we require as we prepare to enter the oral stimulant pouch market." Extensive diligence across North America Doseology's leadership conducted on-site reviews, operational assessments and compliance audits across numerous facilities throughout the United States and Canada. After rigorous evaluation, the company selected a partner recognized for: Certified and compliant production: FDA-registered (U.S. Food and Drug Administration), GMP-certified (good manufacturing practices) and ISO 9001:2015-approved facility ensuring pharmaceutical-grade quality and safety; Turnkey manufacturing expertise: end-to-end solutions spanning formulation, ingredient sourcing, blending, pouch filling, packaging and logistics; Oral pouch specialization: precision control across nicotine, caffeine and nootropic pouch formats -- customizable by dosage, moisture and flavour; Rigorous quality and regulatory systems: built-in QA (quality assurance), traceability and labelling practices fully aligned with FDA and ISO (International Organization for Standardization) standards; Scalable, low-risk partnership model: flexible production volumes that accommodate early pilot runs, regional launches and high-volume commercial production designed to minimize capital investment while accelerating go-to-market. "Our diligence process was deliberate and comprehensive," added Mr. Corkum. "We wanted an American manufacturing partnership that reflects our core values -- integrity, quality and accountability. As we enter the market, this ensures Doseology's products are built on a foundation of trusted North American craftsmanship and scientific precision." A defining milestone for shareholders The signing of this manufacturing agreement by Doseology USA marks a key inflection point in Doseology's investment and commercialization cycle, demonstrating that the company has now established the operational backbone to execute its strategy and deliver measurable progress in the oral stimulant pouch market. "This step validates our readiness to scale," said Mr. Corkum. "We've secured the right partner, the right structure and the right systems to move confidently into the next stage of our growth. For shareholders, this milestone signals tangible execution and a disciplined pathway toward value creation." "This agreement represents a pivotal step in Doseology's ability to commercialize efficiently and responsibly," added Patrick Sills, strategic commercialization adviser to Doseology. "Having worked closely with global category leaders such as Swedish Match, the parent company behind ZYN, I've seen first-hand how disciplined manufacturing, compliance and scalability form the bedrock of long-term success. Doseology's approach -- combining science-driven product development with thoroughly vetted North American infrastructure -- built on the same strategic foundation that defined today's market-leading oral stimulant brands. This partnership validates the company's commitment to execution, quality and shareholder value." Building for market leadership Led by executives with deep experience in regulated Big Tobacco, CPG (consumer packaged goods), nutraceuticals and corporate finance, Doseology continues to build a North American infrastructure network designed to support innovation, compliance and performance at scale. The establishment of Doseology USA further strengthens the company's operational presence in the United States and underscores its commitment to American-made production integrity, sustainable growth and long-term shareholder value. About Doseology Sciences Inc. Doseology is a biotechnology innovation company, engineering precision-formulated oral stimulants that are designed to optimize energy, focus and cognitive performance. Through rigorous scientific research and advanced delivery technologies, Doseology is pioneering next-generation performance solutions designed to empower peak performance. We seek Safe Harbor.